<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02867839</url>
  </required_header>
  <id_info>
    <org_study_id>RESCUE-GC-2016</org_study_id>
    <nct_id>NCT02867839</nct_id>
  </id_info>
  <brief_title>Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer</brief_title>
  <acronym>RESCUE-GC</acronym>
  <official_title>A Randomized, Multicentral, Controlled, Phase III Study to Compare Adjuvant Chemotherapy With S-1 Plus Oxaliplatin to S-1 Alone After Curative Distal Gastrectomy in Locally Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of S-1 plus Oxaliplatin
      versus S-1 only as adjuvant chemotherapy after curative distal gastrectomy in patients with
      locally advanced gastric cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a multi-central, controlled, randomized Phase III trial. The protocol has been
      approved by the Ethics Committee of Beijing Cancer Hospital. The primary endpoint is the
      3-year progression-free survival (PFS) rate. The secondary endpoints are the overall survival
      (OS) and safety.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2017</start_date>
  <completion_date type="Anticipated">February 10, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 10, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 5 years</time_frame>
    <description>To evaluate the 1-year, 3-year and 5-year overall survival of GC patients underwent post-operative chemotherapy of S-1 compared with post-operative SOX</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety]</measure>
    <time_frame>1 year</time_frame>
    <description>The incidence of chemotherapy related adverse events in GC patients underwent post-operative chemotherapy of S-1 compared with post-operative SOX</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">564</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>A: postoperative Oxaliplatin plus S-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in arm A will receive standard distal gastrectomy with D2 lymphadenectomy first, and 8 cycles of adjuvant Oxaliplatin plus S-1 (SOX) later.
Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3W S-1: 40~60mg bid, po, d1~14, q3W (6 months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: postoperative S-1 only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in arm B will receive standard distal gastrectomy with D2 lymphadenectomy first, and 16 cycles of adjuvant S-1 later.
S-1: 40~60mg bid, po, d1~14, q3W (12 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin plus S-1</intervention_name>
    <description>8 cycles of adjuvant chemotherapy with Oxaliplatin plus S-1</description>
    <arm_group_label>A: postoperative Oxaliplatin plus S-1</arm_group_label>
    <other_name>SOX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1 only</intervention_name>
    <description>16 cycles of adjuvant chemotherapy with S-1 only</description>
    <arm_group_label>B: postoperative S-1 only</arm_group_label>
    <other_name>S-1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  sign written informed consent form

          -  age ≥ 18 years, ≤69 years

          -  ECOG status: 0~2

          -  pathologically confirmed gastric cancer at stage II or IIIA (AJCC 7th version)

          -  negative peritoneal cytology

          -  underwent curative distal gastrectomy with D2 lymph node dissection

          -  no prior antitumor treatment is allowed, including chemotherapy, radiotherapy, immune
             therapy or target therapy

          -  adequate organ function as defined below: Hematologic ANC ≥ 2*109/L, Platelets ≥
             100*109/L, AST and ALT ≤ 2.5×ULN, TBIL ≤ 1.5×ULN.

        Exclusion Criteria:

          -  be enrolled in other clinical trials

          -  underwent prior antitumor treatment

          -  allergic reaction to S-1 or oxaliplatin

          -  abnormal GI tract function

          -  female in pregnancy or lactation, or refuse to receive Contraception measures during
             chemotherapy

          -  other situation to be judged not adaptive to the study by investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiafu Ji, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiafu Ji, MD</last_name>
    <phone>0086-10-88196391</phone>
    <email>jiafuj@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Biao Fan, MD, Ph.D</last_name>
    <phone>0086-10-88196970</phone>
    <email>fanbiao1986@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xin Wang, MD</last_name>
      <phone>13691478989</phone>
      <email>wangxin_guo@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Tao Wu, MD</last_name>
      <phone>13671063600</phone>
      <email>drwutao@aliyun.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yingjiang Ye, MD</last_name>
      <phone>13911133682</phone>
      <email>yeyingjiang@pkuph.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Jing Zhou, MD</last_name>
      <email>zhoujing-rmyy@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhongtao Zhang, MD</last_name>
      <phone>13801060364</phone>
      <email>zhangzht@medmail.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xuanwu Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fei Li, MD</last_name>
      <email>fli36@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiafu Ji, MD</last_name>
      <phone>0086-01-88196391</phone>
      <email>jiafuj@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Biao Fan, MD, PhD</last_name>
      <phone>0086-01-88196970</phone>
      <email>fanbiao1986@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jiafu Ji, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhaode Bu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Biao Fan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gang Xiao, MD</last_name>
      <email>xgbj@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lin Chen, MD</last_name>
      <phone>13801290395</phone>
      <email>chenlinbj@vip.sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bin Xiong, MD</last_name>
      <phone>13886029351</phone>
      <email>binxiong1961@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanjing General Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guoli Li, MD</last_name>
      <phone>13851559752</phone>
      <email>13851559752@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Daliang Medical University</name>
      <address>
        <city>Daliang</city>
        <state>Liaoning</state>
        <zip>116011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang Hu, MD</last_name>
      <email>sunnyliangpin@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qingsi He, MD</last_name>
      <phone>13791122955</phone>
      <email>13791122955@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Lian Liu, MD</last_name>
      <email>tounao@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yian Du, MD</last_name>
      <email>duyajim@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xian Shen, MD</last_name>
      <phone>13968888872</phone>
      <email>13968888872@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2016</study_first_submitted>
  <study_first_submitted_qc>August 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <last_update_submitted>November 5, 2017</last_update_submitted>
  <last_update_submitted_qc>November 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Biao Fan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Gastric cancer</keyword>
  <keyword>Adjuvant chemotherapy</keyword>
  <keyword>S1</keyword>
  <keyword>Oxaliplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

